{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T08:17:37Z","timestamp":1790842657804,"version":"4.1.0"},"reference-count":102,"publisher":"MDPI AG","issue":"21","license":[{"start":{"date-parts":[[2021,10,26]],"date-time":"2021-10-26T00:00:00Z","timestamp":1635206400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100006769","name":"Russian Science Foundation","doi-asserted-by":"publisher","award":["19-75-20128"],"award-info":[{"award-number":["19-75-20128"]}],"id":[{"id":"10.13039\/501100006769","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>Chronic myelomonocytic leukemia (CMML) is a rare and challenging type of myeloproliferative neoplasm. Poor prognosis and high mortality, associated predominantly with progression to secondary acute myeloid leukemia (sAML), is still an unsolved problem. Despite a growing body of knowledge about the molecular repertoire of this disease, at present, the prognostic significance of CMML-associated mutations is controversial. The absence of available CMML cell lines and the small number of patients with CMML make pre-clinical testing and clinical trials complicated. Currently, specific therapy for CMML has not been approved; most of the currently available therapeutic approaches are based on myelodysplastic syndrome (MDS) and other myeloproliferative neoplasm (MNP) studies. In this regard, the development of the robust CMML animal models is currently the focus of interest. This review describes important studies concerning animal models of CMML, examples of methodological approaches, and the obtained hematologic phenotypes.<\/jats:p>","DOI":"10.3390\/ijms222111510","type":"journal-article","created":{"date-parts":[[2021,10,26]],"date-time":"2021-10-26T23:49:52Z","timestamp":1635292192000},"page":"11510","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Mouse Models of CMML"],"prefix":"10.3390","volume":"22","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3985-9552","authenticated-orcid":false,"given":"Ekaterina","family":"Belotserkovskaya","sequence":"first","affiliation":[{"name":"Laboratory of Molecular Medicine, Institute of Cytology, Russian Academy of Sciences, 4 Tikhoretskii Prospect, 194064 St. Petersburg, Russia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4323-7174","authenticated-orcid":false,"given":"Oleg","family":"Demidov","sequence":"additional","affiliation":[{"name":"Laboratory of Molecular Medicine, Institute of Cytology, Russian Academy of Sciences, 4 Tikhoretskii Prospect, 194064 St. Petersburg, Russia"},{"name":"Laboratory of Excellence LipSTIC and Label Ligue Nationale Contre le Cancer, 7 Boulevard Jeanne d\u2019Arc, 21000 Dijon, France"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2021,10,26]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1038\/s41379-019-0215-y","article-title":"Update on the Pathologic Diagnosis of Chronic Myelomonocytic Leukemia","volume":"32","author":"Arber","year":"2019","journal-title":"Mod. Pathol."},{"key":"ref_2","first-page":"1400","article-title":"South Thames Haematology Specialist Committee. The Incidence and Outcome of Myeloid Malignancies in 2,112 Adult Patients in Southeast England","volume":"91","author":"Phekoo","year":"2006","journal-title":"Haematologica"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1182\/blood-2008-01-134858","article-title":"Epidemiology of Myelodysplastic Syndromes and Chronic Myeloproliferative Disorders in the United States, 2001\u20132004, Using Data from the NAACCR and SEER Programs","volume":"112","author":"Rollison","year":"2008","journal-title":"Blood"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.canep.2019.01.003","article-title":"Trends of Incidence and Survival of Patients with Chronic Myelomonocytic Leukemia between 1999 and 2014: A Comparison between Swiss and American Population-Based Cancer Registries","volume":"59","author":"Benzarti","year":"2019","journal-title":"Cancer Epidemiol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"55","DOI":"10.3324\/haematol.2010.026252","article-title":"Twenty-Five Years of Epidemiological Recording on Myeloid Malignancies: Data from the Specialized Registry of Hematologic Malignancies of Cote d\u2019Or (Burgundy, France)","volume":"96","author":"Girodon","year":"2011","journal-title":"Haematologica"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1648","DOI":"10.1080\/10428194.2016.1258700","article-title":"Incidence and Survival Outcomes of Chronic Myelomonocytic Leukemia in the United States","volume":"58","author":"Dhakal","year":"2017","journal-title":"Leuk. Lymphoma"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"375","DOI":"10.3324\/haematol.2010.030957","article-title":"Cytogenetic Risk Stratification in Chronic Myelomonocytic Leukemia","volume":"96","author":"Such","year":"2011","journal-title":"Haematologica"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1080\/1042819042000207271","article-title":"Risk Assessment in Chronic Myelomonocytic Leukemia (CMML)","volume":"45","author":"Germing","year":"2004","journal-title":"Leuk. Lymphoma"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1182\/blood.V99.3.840","article-title":"Prognostic Factors and Scoring Systems in Chronic Myelomonocytic Leukemia: A Retrospective Analysis of 213 Patients","volume":"99","author":"Onida","year":"2002","journal-title":"Blood"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1002\/ajh.23962","article-title":"Blast Transformation in Chronic Myelomonocytic Leukemia: Risk Factors, Genetic Features, Survival, and Treatment Outcome","volume":"90","author":"Patnaik","year":"2015","journal-title":"Am. J. Hematol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1111\/j.1365-2141.1994.tb06734.x","article-title":"The Chronic Myeloid Leukaemias: Guidelines for Distinguishing Chronic Granulocytic, Atypical Chronic Myeloid, and Chronic Myelomonocytic Leukaemia: Proposals by the French-American-British Cooperative Leukaemia Group","volume":"87","author":"Bennett","year":"1994","journal-title":"Br. J. Haematol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"2292","DOI":"10.1182\/blood-2002-04-1199","article-title":"The World Health Organization (WHO) Classification of the Myeloid Neoplasms","volume":"100","author":"Vardiman","year":"2002","journal-title":"Blood"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1935","DOI":"10.3324\/haematol.2019.222059","article-title":"Proposed Diagnostic Criteria for Classical Chronic Myelomonocytic Leukemia (CMML), CMML Variants and Pre-CMML Conditions","volume":"104","author":"Valent","year":"2019","journal-title":"Haematologica"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1182\/blood-2009-03-209262","article-title":"The 2008 Revision of the World Health Organization (WHO) Classification of Myeloid Neoplasms and Acute Leukemia: Rationale and Important Changes","volume":"114","author":"Vardiman","year":"2009","journal-title":"Blood"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1111\/ijlh.13145","article-title":"How I Investigate Chronic Myelomonocytic Leukemia","volume":"42","author":"Sangiorgio","year":"2020","journal-title":"Int. J. Lab. Hematol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1987","DOI":"10.1182\/blood.V128.22.1987.1987","article-title":"\u201cProliferative\u201d versus \u201cDysplastic\u201d Chronic Myelomonocytic Leukemia: Molecular and Prognostic Correlates","volume":"128","author":"Patnaik","year":"2016","journal-title":"Blood"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1111\/bjh.12756","article-title":"Chronic Myelomonocytic Leukaemia: A Concise Clinical and Pathophysiological Review","volume":"165","author":"Patnaik","year":"2014","journal-title":"Br. J. Haematol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"2391","DOI":"10.1182\/blood-2016-03-643544","article-title":"The 2016 Revision to the World Health Organization Classification of Myeloid Neoplasms and Acute Leukemia","volume":"127","author":"Arber","year":"2016","journal-title":"Blood"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1002\/ajh.23846","article-title":"Molecular and Prognostic Correlates of Cytogenetic Abnormalities in Chronic Myelomonocytic Leukemia: A Mayo Clinic-French Consortium Study","volume":"89","author":"Wassie","year":"2014","journal-title":"Am. J. Hematol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1002\/ajh.23751","article-title":"Cytogenetic Risk Stratification of 417 Patients with Chronic Myelomonocytic Leukemia from a Single Institution","volume":"89","author":"Tang","year":"2014","journal-title":"Am. J. Hematol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"e393","DOI":"10.1038\/bcj.2016.5","article-title":"Cytogenetic and Molecular Abnormalities in Chronic Myelomonocytic Leukemia","volume":"6","author":"Patnaik","year":"2016","journal-title":"Blood Cancer J."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"2428","DOI":"10.1200\/JCO.2012.47.3314","article-title":"Prognostic Score Including Gene Mutations in Chronic Myelomonocytic Leukemia","volume":"31","author":"Itzykson","year":"2013","journal-title":"J. Clin. Oncol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"3932","DOI":"10.1182\/blood-2010-10-311019","article-title":"Mutational Spectrum Analysis of Chronic Myelomonocytic Leukemia Includes Genes Associated with Epigenetic Regulation: UTX, EZH2, and DNMT3A","volume":"118","author":"Jankowska","year":"2011","journal-title":"Blood"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"e472","DOI":"10.1038\/bcj.2016.82","article-title":"Number and Type of TET2 Mutations in Chronic Myelomonocytic Leukemia and Their Clinical Relevance","volume":"6","author":"Patnaik","year":"2016","journal-title":"Blood Cancer J."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1038\/leu.2011.10","article-title":"Molecular Profiling of Chronic Myelomonocytic Leukemia Reveals Diverse Mutations in >80% of Patients with TET2 and EZH2 Being of High Prognostic Relevance","volume":"25","author":"Grossmann","year":"2011","journal-title":"Leukemia"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1002\/ajh.23373","article-title":"Spliceosome Mutations Involving SRSF2, SF3B1, and U2AF35 in Chronic Myelomonocytic Leukemia: Prevalence, Clinical Correlates, and Prognostic Relevance","volume":"88","author":"Patnaik","year":"2013","journal-title":"Am. J. Hematol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"3080","DOI":"10.1182\/blood-2012-01-404863","article-title":"SRSF2 Mutations in 275 Cases with Chronic Myelomonocytic Leukemia (CMML)","volume":"120","author":"Meggendorfer","year":"2012","journal-title":"Blood"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"3858","DOI":"10.1200\/JCO.2009.27.1361","article-title":"Next-Generation Sequencing Technology Reveals a Characteristic Pattern of Molecular Mutations in 72.8% of Chronic Myelomonocytic Leukemia by Detecting Frequent Alterations in TET2, CBL, RAS, and RUNX1","volume":"28","author":"Kohlmann","year":"2010","journal-title":"J. Clin. Oncol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1002\/ajh.23345","article-title":"FLT3 Mutations in Myelodysplastic Syndrome and Chronic Myelomonocytic Leukemia","volume":"88","author":"Daver","year":"2013","journal-title":"Am. J. Hematol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"2100","DOI":"10.1038\/leu.2013.97","article-title":"SETBP1 Mutations in 415 Patients with Primary Myelofibrosis or Chronic Myelomonocytic Leukemia: Independent Prognostic Impact in CMML","volume":"27","author":"Laborde","year":"2013","journal-title":"Leukemia"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"1441","DOI":"10.1038\/leu.2013.100","article-title":"An Evolutionary Perspective on Chronic Myelomonocytic Leukemia","volume":"27","author":"Itzykson","year":"2013","journal-title":"Leukemia"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1016\/j.ebiom.2018.04.018","article-title":"Prognostic Role of Gene Mutations in Chronic Myelomonocytic Leukemia Patients Treated with Hypomethylating Agents","volume":"31","author":"Duchmann","year":"2018","journal-title":"EBioMedicine"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1038\/leu.2015.337","article-title":"Age-Related Mutations and Chronic Myelomonocytic Leukemia","volume":"30","author":"Mason","year":"2016","journal-title":"Leukemia"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1186\/s40164-015-0009-y","article-title":"Impact of TET2, SRSF2, ASXL1 and SETBP1 Mutations on Survival of Patients with Chronic Myelomonocytic Leukemia","volume":"4","author":"Cui","year":"2015","journal-title":"Exp. Hematol. Oncol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"2206","DOI":"10.1038\/leu.2014.125","article-title":"ASXL1 and SETBP1 Mutations and Their Prognostic Contribution in Chronic Myelomonocytic Leukemia: A Two-Center Study of 466 Patients","volume":"28","author":"Patnaik","year":"2014","journal-title":"Leukemia"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1038\/s41408-017-0004-0","article-title":"ASXL1 Frameshift Mutations Drive Inferior Outcomes in CMML without Negative Impact in MDS","volume":"7","author":"Sallman","year":"2017","journal-title":"Blood Cancer J."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1111\/j.1365-2141.2010.08381.x","article-title":"ASXL1 Mutation Is Associated with Poor Prognosis and Acute Transformation in Chronic Myelomonocytic Leukaemia","volume":"151","author":"Trouplin","year":"2010","journal-title":"Br. J. Haematol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1016\/j.jmoldx.2018.07.002","article-title":"Clinical Significance of DNA Variants in Chronic Myeloid Neoplasms: A Report of the Association for Molecular Pathology","volume":"20","author":"McClure","year":"2018","journal-title":"J. Mol. Diagn."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"e270","DOI":"10.1038\/bcj.2014.90","article-title":"Chronic Myelomonocytic Leukemia in Younger Patients: Molecular and Cytogenetic Predictors of Survival and Treatment Outcome","volume":"5","author":"Patnaik","year":"2015","journal-title":"Blood Cancer J."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"3824","DOI":"10.1182\/blood-2011-05-352039","article-title":"Molecular Predictors of Response to Decitabine in Advanced Chronic Myelomonocytic Leukemia: A Phase 2 Trial","volume":"118","author":"Braun","year":"2011","journal-title":"Blood"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"1857","DOI":"10.1172\/JCI78752","article-title":"Specific Molecular Signatures Predict Decitabine Response in Chronic Myelomonocytic Leukemia","volume":"125","author":"Meldi","year":"2015","journal-title":"J. Clin. Investig."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"1676","DOI":"10.3324\/haematol.2009.011205","article-title":"TET2 Gene Mutation Is a Frequent and Adverse Event in Chronic Myelomonocytic Leukemia","volume":"94","author":"Kosmider","year":"2009","journal-title":"Haematologica"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"3923","DOI":"10.1182\/blood-2010-03-274704","article-title":"Next-Generation Sequencing of the TET2 Gene in 355 MDS and CMML Patients Reveals Low-Abundance Mutant Clones with Early Origins, but Indicates No Definite Prognostic Value","volume":"116","author":"Smith","year":"2010","journal-title":"Blood"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1007\/s12185-014-1670-3","article-title":"Molecular Pathogenesis of Atypical CML, CMML and MDS\/MPN-Unclassifiable","volume":"101","author":"Zoi","year":"2015","journal-title":"Int. J. Hematol."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"2705","DOI":"10.1182\/blood-2014-06-582809","article-title":"TET2 Mutations Predict Response to Hypomethylating Agents in Myelodysplastic Syndrome Patients","volume":"124","author":"Bejar","year":"2014","journal-title":"Blood"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1080\/10245332.2018.1471794","article-title":"Prognostic Significance of SRSF2 Mutations in Myelodysplastic Syndromes and Chronic Myelomonocytic Leukemia: A Meta-Analysis","volume":"23","author":"Ayatollahi","year":"2018","journal-title":"Hematology"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"1426","DOI":"10.1038\/leu.2009.48","article-title":"RUNX1 Mutations Are Frequent in Chronic Myelomonocytic Leukemia and Mutations at the C-Terminal Region Might Predict Acute Myeloid Leukemia Transformation","volume":"23","author":"Kuo","year":"2009","journal-title":"Leukemia"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"2901","DOI":"10.1038\/s41467-021-23186-w","article-title":"RAS Mutations Drive Proliferative Chronic Myelomonocytic Leukemia via a KMT2A-PLK1 Axis","volume":"12","author":"Carr","year":"2021","journal-title":"Nat. Commun."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1002\/ajh.25684","article-title":"Chronic Myelomonocytic Leukemia: 2020 Update on Diagnosis, Risk Stratification and Management","volume":"95","author":"Patnaik","year":"2020","journal-title":"Am. J. Hematol."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1002\/ajh.24581","article-title":"DNMT3A Mutations Are Associated with Inferior Overall and Leukemia-Free Survival in Chronic Myelomonocytic Leukemia","volume":"92","author":"Patnaik","year":"2017","journal-title":"Am. J. Hematol."},{"key":"ref_51","doi-asserted-by":"crossref","unstructured":"Shou, L.-H., Cao, D., Dong, X.-H., Fang, Q., Wu, Y., Zhang, Y., Fei, J.-P., and Xu, B.-L. (2017). Prognostic Significance of SETBP1 Mutations in Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, and Chronic Neutrophilic Leukemia: A Meta-Analysis. PLoS ONE, 12.","DOI":"10.1371\/journal.pone.0171608"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"1401","DOI":"10.1038\/leu.2013.35","article-title":"SETBP1 Mutations in 658 Patients with Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia and Secondary Acute Myeloid Leukemias","volume":"27","author":"Damm","year":"2013","journal-title":"Leukemia"},{"key":"ref_53","first-page":"5716","article-title":"SF3B1-Mutant CMML Defines a Predominantly Dysplastic CMML Subtype with a Superior Acute Leukemia-Free Survival","volume":"4","author":"Wudhikarn","year":"2020","journal-title":"Blood Adv."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"10767","DOI":"10.1038\/ncomms10767","article-title":"Mutation Allele Burden Remains Unchanged in Chronic Myelomonocytic Leukaemia Responding to Hypomethylating Agents","volume":"7","author":"Merlevede","year":"2016","journal-title":"Nat. Commun."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"2815","DOI":"10.1038\/leu.2017.164","article-title":"Genomic Determinants of Chronic Myelomonocytic Leukemia","volume":"31","author":"Patel","year":"2017","journal-title":"Leukemia"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.1182\/blood-2014-03-560227","article-title":"Driver Somatic Mutations Identify Distinct Disease Entities within Myeloid Neoplasms with Myelodysplasia","volume":"124","author":"Malcovati","year":"2014","journal-title":"Blood"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1182\/blood-2015-03-631747","article-title":"Clonal Hematopoiesis of Indeterminate Potential and Its Distinction from Myelodysplastic Syndromes","volume":"126","author":"Steensma","year":"2015","journal-title":"Blood"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"e48","DOI":"10.1002\/acg2.48","article-title":"Advances in Chronic Myelomonocytic Leukemia and Future Prospects: Lessons Learned from Precision Genomics","volume":"2","author":"Mangaonkar","year":"2019","journal-title":"Adv. Cell Gene Ther."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1002\/ajh.23702","article-title":"Gene Mutations Differently Impact the Prognosis of the Myelodysplastic and Myeloproliferative Classes of Chronic Myelomonocytic Leukemia","volume":"89","author":"Cervera","year":"2014","journal-title":"Am. J. Hematol."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"e150","DOI":"10.1097\/HS9.0000000000000150","article-title":"Diagnosis and Treatment of Chronic Myelomonocytic Leukemias in Adults: Recommendations from the European Hematology Association and the European LeukemiaNet","volume":"2","author":"Itzykson","year":"2018","journal-title":"HemaSphere"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1007\/s11899-019-00509-9","article-title":"Chronic Myelomonocytic Leukemia: 2018 Update to Prognosis and Treatment","volume":"14","author":"Elmariah","year":"2019","journal-title":"Curr. Hematol. Malig. Rep."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1016\/j.bbmt.2010.09.018","article-title":"Allogeneic Hematopoietic Cell Transplantation for Chronic Myelomonocytic Leukemia: Relapse-Free Survival Is Determined by Karyotype and Comorbidities","volume":"17","author":"Eissa","year":"2011","journal-title":"Biol. Blood Marrow Transplant."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"1753","DOI":"10.1182\/blood-2016-06-724500","article-title":"Allogeneic Hematopoietic Stem Cell Transplantation for MDS and CMML: Recommendations from an International Expert Panel","volume":"129","author":"Bowen","year":"2017","journal-title":"Blood"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1002\/ajh.24396","article-title":"Chronic Myelomonocytic Leukemia: 2016 Update on Diagnosis, Risk Stratification, and Management","volume":"91","author":"Patnaik","year":"2016","journal-title":"Am. J. Hematol."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1002\/ajh.24735","article-title":"Natural History of Chronic Myelomonocytic Leukemia Treated with Hypomethylating Agents","volume":"92","author":"Alfonso","year":"2017","journal-title":"Am. J. Hematol."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1007\/s11899-017-0408-8","article-title":"Therapy for Chronic Myelomonocytic Leukemia in a New Era","volume":"12","author":"Moyo","year":"2017","journal-title":"Curr. Hematol. Malig. Rep."},{"key":"ref_67","first-page":"162","article-title":"Promising Results of a Phase 1\/2 Clinical Trial of Ruxolitinib in Patients with Chronic Myelomonocytic Leukemia","volume":"130","author":"Padron","year":"2017","journal-title":"Blood"},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"4158","DOI":"10.1182\/blood-2006-07-035725","article-title":"A Multicenter Phase 2 Study of the Farnesyltransferase Inhibitor Tipifarnib in Intermediate- to High-Risk Myelodysplastic Syndrome","volume":"109","author":"Fenaux","year":"2007","journal-title":"Blood"},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1002\/ajh.25104","article-title":"Chronic Myelomonocytic Leukemia: 2018 Update on Diagnosis, Risk Stratification and Management","volume":"93","author":"Patnaik","year":"2018","journal-title":"Am. J. Hematol."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1080\/10428194.2017.1369070","article-title":"A Phase I Study of Lenalidomide in Patients with Chronic Myelomonocytic Leukemia (CMML)\u2014AGMT_CMML-1","volume":"59","author":"Burgstaller","year":"2018","journal-title":"Leuk. Lymphoma"},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"e63","DOI":"10.1016\/S2352-3026(18)30002-4","article-title":"Sotatercept with Long-Term Extension for the Treatment of Anaemia in Patients with Lower-Risk Myelodysplastic Syndromes: A Phase 2, Dose-Ranging Trial","volume":"5","author":"Komrokji","year":"2018","journal-title":"Lancet Haematol."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"3251","DOI":"10.1182\/blood.V124.21.3251.3251","article-title":"An Open-Label, Phase 2, Dose-Finding Study of Sotatercept (ACE-011) in Patients with Low or Intermediate-1 (Int-1)-Risk Myelodysplastic Syndromes (MDS) or Non-Proliferative Chronic Myelomonocytic Leukemia (CMML) and Anemia Requiring Transfusion","volume":"124","author":"Komrokji","year":"2014","journal-title":"Blood"},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"1471","DOI":"10.1182\/blood.V89.5.1471","article-title":"The Structural and Functional Basis of Cytokine Receptor Activation: Lessons from the Common \u03b2 Subunit of the Granulocyte-Macrophage Colony-Stimulating Factor, Interleukin-3 (IL-3), and IL-5 Receptors","volume":"89","author":"Bagley","year":"1997","journal-title":"Blood"},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1182\/blood.V92.3.867","article-title":"Characterization of the Role of the Human Granulocyte-Macrophage Colony-Stimulating Factor Receptor \u03b1 Subunit in the Activation of JAK2 and STAT5","volume":"92","author":"Doyle","year":"1998","journal-title":"Blood"},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1038\/ng0296-137","article-title":"Nf1 Deficiency Causes Ras-Dediated Granulocyte\/Macrophage Colony Stimulating Factor Hypersensitivity and Chronic Myeloid Leukaemia","volume":"12","author":"Largaespada","year":"1996","journal-title":"Nat. Genet."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/S1097-2765(00)80415-3","article-title":"Nf1 and Gmcsf Interact in Myeloid Leukemogenesis","volume":"5","author":"Birnbaum","year":"2000","journal-title":"Mol. Cell"},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"5991","DOI":"10.1182\/blood-2010-04-281527","article-title":"Endogenous Oncogenic Nras Mutation Promotes Aberrant GM-CSF Signaling in Granulocytic\/Monocytic Precursors in a Murine Model of Chronic Myelomonocytic Leukemia","volume":"116","author":"Wang","year":"2010","journal-title":"Blood"},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"19093","DOI":"10.1074\/jbc.M115.653154","article-title":"Deficiency of \u03b2 Common Receptor Moderately Attenuates the Progression of Myeloproliferative Neoplasm in NrasG12D\/+ Mice","volume":"290","author":"Zhang","year":"2015","journal-title":"J. Biol. Chem."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1182\/blood-2010-12-326058","article-title":"Endogenous Oncogenic Nras Mutation Initiates Hematopoietic Malignancies in a Dose- and Cell Type-Dependent Manner","volume":"118","author":"Wang","year":"2011","journal-title":"Blood"},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1172\/JCI20476","article-title":"Conditional Expression of Oncogenic K-Ras from Its Endogenous Promoter Induces a Myeloproliferative Disease","volume":"113","author":"Chan","year":"2004","journal-title":"J. Clin. Investig."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"1847","DOI":"10.1038\/leu.2015.85","article-title":"Loss of Dnmt3a and Endogenous Kras(G12D\/+) Cooperate to Regulate Hematopoietic Stem and Progenitor Cell Functions in Leukemogenesis","volume":"29","author":"Chang","year":"2015","journal-title":"Leukemia"},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1182\/blood-2017-10-811760","article-title":"USP22 Deficiency Leads to Myeloid Leukemia upon Oncogenic Kras Activation through a PU.1-Dependent Mechanism","volume":"132","author":"Xu","year":"2018","journal-title":"Blood"},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1038\/leu.2008.162","article-title":"Juvenile Myelomonocytic Leukemia and Chronic Myelomonocytic Leukemia","volume":"22","author":"Emanuel","year":"2008","journal-title":"Leukemia"},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"2148","DOI":"10.1182\/blood-2016-06-724658","article-title":"Acquired Expression of Cbl(Q367P) in Mice Induces Dysplastic Myelopoiesis Mimicking Chronic Myelomonocytic Leukemia","volume":"129","author":"Nakata","year":"2017","journal-title":"Blood"},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"1859","DOI":"10.1182\/blood-2009-01-198416","article-title":"Mutations in CBL Occur Frequently in Juvenile Myelomonocytic Leukemia","volume":"114","author":"Loh","year":"2009","journal-title":"Blood"},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"4509","DOI":"10.1182\/blood-2010-12-325241","article-title":"Deletion of Tet2 in Mice Leads to Dysregulated Hematopoietic Stem Cells and Subsequent Development of Myeloid Malignancies","volume":"118","author":"Li","year":"2011","journal-title":"Blood"},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"5455","DOI":"10.1038\/s41467-018-07801-x","article-title":"A MiR-150\/TET3 Pathway Regulates the Generation of Mouse and Human Non-Classical Monocyte Subset","volume":"9","author":"Ghamlouch","year":"2018","journal-title":"Nat. Commun."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1186\/s13045-019-0789-3","article-title":"RUNX1 Mutations Promote Leukemogenesis of Myeloid Malignancies in ASXL1-Mutated Leukemia","volume":"12","author":"Bera","year":"2019","journal-title":"J. Hematol. Oncol."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"2491","DOI":"10.1182\/bloodadvances.2018024166","article-title":"KDM6B Overexpression Activates Innate Immune Signaling and Impairs Hematopoiesis in Mice","volume":"2","author":"Wei","year":"2018","journal-title":"Blood Adv."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"1458","DOI":"10.1038\/s41375-018-0011-6","article-title":"Utx Loss Causes Myeloid Transformation","volume":"32","author":"Zheng","year":"2018","journal-title":"Leukemia"},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1182\/bloodadvances.2018025007","article-title":"NUP98-HBO1-Fusion Generates Phenotypically and Genetically Relevant Chronic Myelomonocytic Leukemia Pathogenesis","volume":"3","author":"Hayashi","year":"2019","journal-title":"Blood Adv."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.1093\/jnci\/djn253","article-title":"Identification of Chromatin Remodeling Genes Arid4a and Arid4b as Leukemia Suppressor Genes","volume":"100","author":"Wu","year":"2008","journal-title":"J. Natl. Cancer Inst."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"2361","DOI":"10.1172\/JCI45213","article-title":"Transcription Intermediary Factor 1\u03b3 Is a Tumor Suppressor in Mouse and Human Chronic Myelomonocytic Leukemia","volume":"121","author":"Aucagne","year":"2011","journal-title":"J. Clin. Investig."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"10592","DOI":"10.1073\/pnas.1405546111","article-title":"Tif1\u03b3 Regulates the TGF-\u03921 Receptor and Promotes Physiological Aging of Hematopoietic Stem Cells","volume":"111","author":"Carmignac","year":"2014","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1101\/gad.1045603","article-title":"Proapoptotic BID Is Required for Myeloid Homeostasis and Tumor Suppression","volume":"17","author":"Zinkel","year":"2003","journal-title":"Genes Dev."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"57","DOI":"10.4252\/wjsc.v10.i6.57","article-title":"Murine Models Based on Acute Myeloid Leukemia-Initiating Stem Cells Xenografting","volume":"10","author":"Mambet","year":"2018","journal-title":"World J. Stem Cells"},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1182\/blood-2017-01-763219","article-title":"Robust Patient-Derived Xenografts of MDS\/MPN Overlap Syndromes Capture the Unique Characteristics of CMML and JMML","volume":"130","author":"Yoshimi","year":"2017","journal-title":"Blood"},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1038\/s41598-018-34193-1","article-title":"Using Patient-Derived IPSCs to Develop Humanized Mouse Models for Chronic Myelomonocytic Leukemia and Therapeutic Drug Identification, Including Liposomal Clodronate","volume":"8","author":"Taoka","year":"2018","journal-title":"Sci. Rep."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"3390","DOI":"10.1182\/blood.2020008729","article-title":"Cytokine-like Protein 1-Induced Survival of Monocytes Suggests a Combined Strategy Targeting MCL1 and MAPK in CMML","volume":"137","author":"Sevin","year":"2021","journal-title":"Blood"},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"972","DOI":"10.1182\/bloodadvances.2017004903","article-title":"Engraftment of Chronic Myelomonocytic Leukemia Cells in Immunocompromised Mice Supports Disease Dependency on Cytokines","volume":"1","author":"Zhang","year":"2017","journal-title":"Blood Adv."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"2951","DOI":"10.1038\/s41375-020-0929-3","article-title":"Effective Drug Treatment Identified by in Vivo Screening in a Transplantable Patient-Derived Xenograft Model of Chronic Myelomonocytic Leukemia","volume":"34","author":"Kloos","year":"2020","journal-title":"Leukemia"},{"key":"ref_102","doi-asserted-by":"crossref","unstructured":"Hunter, A.M., Newman, H., DeZern, A.E., Steensma, D.P., Niyongere, S., Roboz, G.J., Mo, Q., Chan, O., Gerds, A., and Sallman, D.A. (2021). Integrated Human and Murine Clinical Study Establishes Clinical Efficacy of Ruxolitinib in Chronic Myelomonocytic Leukemia. Clin. Cancer Res.","DOI":"10.1158\/1078-0432.CCR-21-0935"}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/22\/21\/11510\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T07:23:27Z","timestamp":1760167407000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/22\/21\/11510"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10,26]]},"references-count":102,"journal-issue":{"issue":"21","published-online":{"date-parts":[[2021,11]]}},"alternative-id":["ijms222111510"],"URL":"https:\/\/doi.org\/10.3390\/ijms222111510","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,10,26]]}}}